Jasbir Seehra - Apr 8, 2023 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Executive Officer, Director
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Apr 8, 2023
Transactions value $
$1,920
Form type
4
Date filed
4/11/2023, 04:05 PM
Previous filing
Feb 17, 2023
Next filing
Feb 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $1.92K +4K +1.61% $0.48* 253K Apr 8, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -4K -8.15% $0.00 45.1K Apr 8, 2023 Common Stock 4K $0.48 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested and exercisable.